KB004, a First-in-Class Monoclonal Antibody Targeting the Receptor Tyrosine Kinase EphA3 in Patients with Advanced Hematologic Malignancies: Results from a Phase 1 study. Leukemia Research Swords, R. T., Greenberg, P. L., et al 2016; 50: 123-131